Announcements Trials
Browse Landscape

Phase

Phase 2/3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Lung Neoplasms 15Carcinoma, Non-Small-Cell Lung 10Ovarian Neoplasms 8Carcinoma, Hepatocellular 7Urinary Bladder Neoplasms 6Fallopian Tube Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Melanoma 5Colorectal Neoplasms 5Carcinoma, Renal Cell 5Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Endometrial Neoplasms 4Nasopharyngeal Carcinoma 3Mouth Neoplasms 3Glioblastoma 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Oropharyngeal Neoplasms 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2

Interventions

Cisplatin 22Magnetic Resonance Spectroscopy 15Specimen Handling 13Platinum 12Radiotherapy, Intensity-Modulated 111,2-diaminocyclohexaneplatinum II citrate 11Radiotherapy 10Radiation 10Carboplatin 9Surveys and Questionnaires 5Biopsy 5pembrolizumab 4Taxes 4Paclitaxel 4Nivolumab 4Docetaxel 4Chemoradiotherapy 4Cetuximab 4Observation 3Fluorodeoxyglucose F18 3(225)Ac-DOTA-c(RGDyK) 3durvalumab 2X-Rays 2Watchful Waiting 2Standard of Care 2Radiotherapy, Image-Guided 2Interviews as Topic 2Immunoglobulin G 2Fluorouracil 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Oropharyngeal Neoplasms × Immunoglobulin G × 90 days × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡